Beta© 2026 Adaptrex, LLC
Beta© 2026 Adaptrex, LLC
Federal grant · project grant (b)
Mutational Profiling in Human Cells as an in Vitro Alternative to in Vivo Mutagenicity Assessments - Project Summary Mutations Are Heritable Changes in the Cellular Genome and Are Key Events in the Induction of Cancer, Birth Defects, and Neurological Diseases. the Lack of a Mutagenicity Bioassay in Human Cells Is a Major Data Gap in the Genetic Toxicology Test Battery Used by Regulatory Agencies for Hazard Identification and Quantitative Risk Assessments. Scitovation Is Developing a New Approach Methodologies (NAMS) Combining Human Cells and Error Corrected Next Generation Sequencing as an in Vitro Alternative to Current Regulatory Mammalian Cell Mutagenicity Assessment Using Rodent Cell Lines, and as an in Vitro Alternative to in Vivo Mutation Assays.
Committed
$1.8 Million
Paid out
$1.7M
95%
Committed, not yet paid
$94.0K
5%
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…